Flavahan WA, Drier Y, Johnstone SE, et al. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature. 2019;575(7781):229-233. doi:10.1038/s41586-019-1668-3
Wardell CP, Fujita M, Yamada T, et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol. 2018;68(5):959-969. doi:10.1016/j.jhep.2018.01.009
Yuan TL, Amzallag A, Bagni R, et al. Differential Effector Engagement by Oncogenic KRAS. Cell Rep. 2018;22(7):1889-1902. doi:10.1016/j.celrep.2018.01.051
Gilles ME, Hao L, Huang L, et al. Personalized RNA Medicine for Pancreatic Cancer. Clin Cancer Res. 2018;24(7):1734-1747. doi:10.1158/1078-0432.CCR-17-2733
Schaub FX, Dhankani V, Berger AC, et al. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Syst. 2018;6(3):282-300.e2. doi:10.1016/j.cels.2018.03.003
Platt RJ, Chen S, Zhou Y, et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014;159(2):440-55. doi:10.1016/j.cell.2014.09.014
Ryan RJH, Drier Y, Whitton H, et al. Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma. Cancer Discov. 2015;5(10):1058-71. doi:10.1158/2159-8290.CD-15-0370
Kim E, Ilic N, Shrestha Y, et al. Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. Cancer Discov. 2016;6(7):714-26. doi:10.1158/2159-8290.CD-16-0160
Flavahan WA, Drier Y, Liau BB, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature. 2016;529(7584):110-4. doi:10.1038/nature16490
Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3(12):1355-63. doi:10.1158/2159-8290.CD-13-0310